Sialidase‐Based Anti–Influenza Virus Therapy Protects against Secondary Pneumococcal Infection

Abstract

These data indicate that DAS181 treatment does not exacerbate secondary bacterial infection in mice. DAS181 may reduce the risk of secondary bacterial infection by inhibiting IFV.